Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 9
Abstract
We have developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate, part of a method we call “KORTUC II”. This study aimed to evaluate the safety and effectiveness of KORTUC II specifically for patients with chemotherapy-resistant supraclavicular lymph node metastasis (KORTUC-SC). Twelve patients were enrolled after providing fully informed written consent. Most of the patients underwent PET-CT examinations prior to and 3-8 months after KORTUC-SC, and every 6 months thereafter if possible. The patients’ age ranged from 58 to 77. The radiotherapy regimen was 4 Gy/ fraction, 3 fractions/ week, for 4 weeks, and the total dose was 48 Gy. The injection of 3 to 6 mL of the agent was started from the fifth radiotherapy fraction, and it was performed twice a week under ultrasonographic guidance. Therapeutic effects were evaluated by PET-CT examinations performed before and after KORTUC-SC treatment. The patients were well tolerated with minimal adverse effects. Of the 12 patients, 4, 5, 2 and 1 patient showed complete response, partial response, stable disease and progressive disease, respectively. The overall survival rate was 83% at 1 year and 75% at 2 years. The mean duration of follow-up at the end of February 2011 was 35.1 months. Based on the PET-CT studies, remarkable therapeutic effects of the KORTUC II treatment were clearly identified. The treatment outcomes were satisfactory. Well-designed, prospective, randomized, clinical trials are needed to confirm the therapeutic efficacy of KORTUC-SC.
Authors and Affiliations
Aoyama N, Ogawa Y, Kubota K, Ohgi K, Kataoka Y, Miyatake K, Tadokoro M, Yamanishi T, Hamada N, Ohnishi T, Kariya S, Tamura T, Nogami M, Nishioka A, Onogawa M, Miyahara M
Keywords
Related Articles
- EP ID EP551804
- DOI 10.14312/2052-4994.2013-32
- Views 56
- Downloads 0
Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer
Introduction: Bevacizumab was approved for treatment of advanced non-squamous, non-small cell lung cancer (NSCLC) in the US in late 2006. Information on its uptake and patient and tumor factors associated with its use is...
Predictive and prognostic value of classification by immunohistochemical phenotypes in localised breast cancer treated with dose-dense adriamycin/cyclophosphamide
Introduction: Histopathologic subtyping according to the St. Gallen classification is predictive of response in women with breast cancer treated with neoadjuvant chemotherapy (NCT). Our aim was to confirm its predictive...
Antioxidant activity of some benzimidazole derivatives to definite tumor cell lines
A group of bis(benzimidazol-2-yl) amines have been already evaluated for cytotoxicity in vitro to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells and two of them (B1 and B2...
Intra-observer agreement in single and joint double readings of contrast-enhanced breast MRI screening for women with high genetic breast cancer risks
Objectives: To examine intra-observer reliability (IR) for lesion detection on contrast-enhanced breast magnetic resonance images (MRI) for screening women at high risk of breast cancer in single and joint double reading...
O-acetylated gangliosides: Structure, biosynthesis, immunogenicity, functions and their potential for cancer immunotherapy
Sialic acid O-acetylation is a developmentally regulated modification of gangliosides implicated in ontogeny and tumor progression. Their existence has been underestimated in the past because of their alkali-labile natur...